Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. - Wikidata - wikimedia - TriplyDB

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

http://www.wikidata.org/entity/Q44120544

about

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab Breast cancer in the personal genomics era Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Essential function for ErbB3 in breast cancer proliferation Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Cardiac toxicity of trastuzumab in elderly patients with breast cancer Changing strategies for target therapy in gastric cancer Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy Targeting of erbB3 receptor to overcome resistance in cancer treatment HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges Role of pertuzumab in the treatment of HER2-positive breast cancer Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Monoclonal antibodies for the treatment of cancer An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer Mechanisms of action of therapeutic antibodies for cancer HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer Cellular effects of HER3-specific affibody molecules Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me Pseudokinases: update on their functions and evaluation as new drug targets.Antibody-based imaging of HER-2: moving into the clinic.Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Antibodies as therapeutic agents: vive la renaissance!

P2860

Q21284978-FE7C3B0A-9E7B-409C-9840-ACE0F34C1A35 Q24313194-FB1180B9-F488-4D5D-98BB-C6533EA3AF94 Q24602679-66682227-E4AB-437D-954F-6CC2A4A7ADA8 Q24603941-5267F3DE-777E-47A6-A5C3-8243971944BE Q24613186-069D729C-8766-4D7E-8A22-D456F58DA8F2 Q24652481-1E0EAEF3-8517-476E-95E6-349EBDFBB098 Q24678674-F90C31FE-A149-4D6B-9892-9B5D14D878D2 Q24795054-8BB29FFD-7C55-42FF-8FC0-8D608C884329 Q24813543-AC7F1944-4EAE-46FC-A755-6D20E511CFA1 Q26741182-F4D507ED-7EDD-4128-843E-C5D622AFD02F Q26774513-2B36A477-A517-4F9D-BC46-A9AC12F14FA0 Q26777681-4ACFEFF6-9538-4D80-9738-A871DFBA8D25 Q26822730-EAB70015-BF1B-4E13-B9BA-4C700A6BFFF5 Q26824462-B0E386D5-A32B-4080-A7D9-1CAA2C036CDB Q26864668-53448B73-8D58-4E7F-9BB9-05A5E16E2C8C Q26866534-ADBD9F4D-4718-4221-A46B-82F319B7B050 Q26995399-D632041A-2270-43DA-9947-271491B9DA9C Q27002386-2EA628AB-A8EA-443E-AB35-A3165891BF9F Q27015224-6E44C075-6FE6-430F-B8BB-7C11F5AA831A Q27025966-C6954FD5-7BAB-4A64-BAF4-6ED4917BBF81 Q27679463-82B6410F-09B5-4EC9-BB97-93617BC27962 Q27683825-08FFFF67-AC6E-4E98-AD24-E021486B0F62 Q27824846-79CB9ABC-00DF-4F40-B364-32A9E222DB34 Q27851691-D04CF832-53B9-4D29-9F7A-83C238C6CEF8 Q27853067-8206049B-414F-4CB6-8E90-D58BFF02B6D9 Q28083123-41FFCC63-2AA3-40C9-9B27-65D3C465B7B7 Q28084982-5ABF3B81-5308-4922-B3CA-6FEB81C26DD7 Q28237833-BF8E879B-8C09-42DF-B5DC-BE00587B559E Q28385366-0F57EADE-1ACE-407F-941D-39E4042373F2 Q28476604-1326422C-3061-420F-B010-03708E145A3D Q28727774-0F9DB73B-CB23-414E-AFBB-4D1B0E242D3F Q28727939-01A76EEB-C3DF-4892-BA6B-33B039DDAF34 Q28729944-3610042A-0714-46CC-B1EC-C157B2B86247 Q30376023-F94DE9B9-5ED0-47E2-A46A-89E433EB7108 Q30397636-A355F95E-CD6C-4815-B8B0-46321D26126A Q30423880-DBE5F757-32E5-4D90-8E75-AF4D3738587B Q30480832-6E10F046-0942-4820-A815-D918B5C69F69 Q30524738-524DDC03-EFAA-4154-91E4-1D84ABBF248C Q30839490-AFE9FB7B-5CF3-4F4B-AA4B-1A7F8C486DAF Q33193524-DF89AFB1-7E13-4C5F-A63B-7EA1B936E986

P2860

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

http://www.wikidata.org/entity/Q44120544

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

@en

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

@nl

type

label

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

@en

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

@nl

prefLabel

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

@en

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

@nl

P1433

Q44120544-30FFA8E2-CA0E-4A76-96BC-C37652015B6A

P1476

Q44120544-E7AF36A4-D7AD-4DB0-BE26-D78C7ACFAFAC

P2093

Q44120544-0C3A6781-81C9-477F-8DF2-54D8FF5C2A63

Q44120544-29E59012-F479-4A46-9733-B312346330AB

Q44120544-3B34F518-90F9-42A0-B96F-E06E7AF88DC6

Q44120544-461A505C-09D5-42A8-8A8F-996E59DF28A7

Q44120544-485F7E11-AF48-4CC0-AB29-08F34A764162

Q44120544-82D2E2FF-C921-4C77-929A-8A80774CC900

Q44120544-95B64DDE-FF01-4E7C-A81C-D6A5F885D2D6

Q44120544-A055C788-B953-4A66-AB69-A8EDB4D0D035

Q44120544-A221BAF6-12AA-4EE2-8A56-5FA394D31B47

Q44120544-A4B4B82B-B666-48B4-82E7-7DE2506C851C

P304

Q44120544-1823FE5A-FAA5-455A-B24E-5B9E4FFA5F8F

P31

Q44120544-7F82A911-75AB-4D88-86E6-375B4E615D1D

P356

Q44120544-577FE13A-60DF-413D-99EF-D1D64D0CE656

P433

Q44120544-30409880-6A99-4B65-B7EE-601F7FEC38E9

P478

Q44120544-28F0C4C6-1430-43DA-8B98-0422E9A11252

P577

Q44120544-C8DA268B-297E-49C9-AF2B-EA02D5EFB18F

P698

Q44120544-2254B9F9-FA43-4459-847B-75124FB75308

P356

S1535-6108(02)00097-1

P1433

P1476

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

@en

P2093

Brian Higgins

http://www.w3.org/2001/XMLSchema#string

Charles Tindell

http://www.w3.org/2001/XMLSchema#string

David B Agus

http://www.w3.org/2001/XMLSchema#string

Douglas P Evans

http://www.w3.org/2001/XMLSchema#string

Gail D Lewis

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Julie A Lofgren

http://www.w3.org/2001/XMLSchema#string

Krista Maiese

http://www.w3.org/2001/XMLSchema#string

Mark X Sliwkowski

http://www.w3.org/2001/XMLSchema#string

Paul I Pisacane

http://www.w3.org/2001/XMLSchema#string

P304

127-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1535-6108(02)00097-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12204533

http://www.w3.org/2001/XMLSchema#string